The new tirzepatide resistance training trial found less lean tissue loss and better strength with supervised exercises against weights and other resistance. Lean tissue includes muscle, organs and water, but excludes fat and bone. Both groups still lost some. Weight loss was similar.
As of November 12, 2026, the day this article was written, T-REx, published November 9 in Nature Medicine, adds direct evidence about protecting strength during tirzepatide treatment.
What the tirzepatide resistance training trial asked
Could adding strength training limit lean tissue loss while people took tirzepatide? Could strength improve even while body weight fell?
Earlier research had already raised the tissue question. The broader SURMOUNT-1 results describe weight loss and a smaller study of fat and lean tissue. T-REx asked what supervised training adds from the start of treatment.
It was randomized, meaning group assignment happened by chance. Everyone received tirzepatide. One group continued usual activities; the other added training. There was no group receiving a placebo, a treatment without the active drug. The comparison therefore tests added exercise, rather than tirzepatide against no medication.
Who took part and what the program involved
The single-center study in Perth, Australia, included 120 adults aged 50–70: 60 men and 60 women past menopause. Participants had obesity, or overweight with a weight-related condition, and were initially inactive.
People with diabetes or cardiovascular disease, meaning disease of the heart or blood vessels, were excluded. None took blood-pressure medicines or statins, medicines that lower cholesterol. Those limits matter when applying the findings to everyday care.
There were 61 people in the usual-activity group and 59 in the training group. The trial's program involved three supervised, one-hour gym sessions weekly for 40 weeks. Exercises became harder gradually under trained supervision. Average attendance was 91%; 111 participants completed the study.
The ANZCTR record, ACTRN12623001236684, describes the planned comparison. This was a supported research program, not a workout prescription for every person taking tirzepatide.
What the scans and strength tests measured
The two main outcomes were changes in fat mass and lean soft tissue mass. Researchers used DXA, a low-dose X-ray scan that separates fat, bone mineral and lean soft tissue. Measurements were repeated every eight weeks.
That scan cannot turn every kilogram of lean tissue lost into a kilogram of muscle lost. The person analyzing the scans did not know group assignments.
Strength was measured separately: the greatest weight someone could lift once on bench press, lat pulldown and knee extension tests. The testers could also supervise exercise sessions, so they could know who trained. Standardized testing reduced, but could not remove, that possible source of bias.
The results: similar weight loss, different strength
Lean tissue loss averaged 3.57 kg with training versus 4.67 kg with usual activities. The paper's analysis put the difference between groups at 1.09 kg. Training limited the loss; it did not eliminate it.
The T-REx paper's 40-week estimates were:
| Change | Tirzepatide + usual activities | Tirzepatide + training |
|---|---|---|
| Body weight | −22.61 kg | −22.28 kg |
| Fat mass | −17.19 kg | −17.98 kg |
| Lean soft tissue | −4.67 kg | −3.57 kg |
| Bench press strength | −4.09 kg | +4.68 kg |
| Knee extension strength | −4.42 kg | +5.88 kg |
Weight and fat loss were similar across groups. Strength moved in opposite directions: it fell with usual activities and rose with training (Green and colleagues, Nature Medicine, 2026).
That is the useful distinction for someone watching the scale. Similar weight changes can sit beside quite different changes in what the body can lift.
Side effects reported in the paper
Stomach and bowel symptoms were common. About half of participants reported nausea. Extended Data Table 5 gives these figures; each entry is people reporting the event, with the percentage in parentheses:
| Event | Usual activities, 61 people | Training, 59 people |
|---|---|---|
| Nausea | 32 (52.5%) | 34 (57.6%) |
| Vomiting | 10 (16.4%) | 17 (28.8%) |
| Constipation | 17 (27.9%) | 21 (35.6%) |
| Diarrhea | 15 (24.6%) | 20 (33.9%) |
People could report more than one symptom. Six participants withdrew because of adverse events, meaning health problems occurring during the study. Six serious events occurred: five with usual activities and one with training. Investigators judged these unrelated to the study treatments (T-REx safety results). A small trial cannot settle uncommon risks.
What the finding does and does not mean
For a person prescribed tirzepatide, the study supports discussing strength alongside weight. The practical exercise guide covers the broader treatment conversation. This trial adds evidence for a particular supervised program.
It does not establish the best routine, prove that everyone needs three weekly sessions, or show that the same results follow from unsupervised workouts. Participants received guidance to maintain protein intake, but the study did not assign a specific diet.
The report also does not establish fewer falls, fewer fractures or easier daily activities over the long term. Better lifting results are encouraging; those other outcomes still need testing.
Where semaglutide fits
As of November 12, 2026, the day this article was written, a November 12 study, which observed rather than assigned treatments, found the tirzepatide–semaglutide lean-tissue difference disappeared after accounting for weight loss; the comparison review explains it.
T-REx itself did not include a semaglutide group. It therefore cannot establish which medicine better preserves muscle. The separate semaglutide muscle-loss guide explains that medicine's evidence. A comparison between medications and a trial of added exercise answer different questions.
What to watch next and discuss at a visit
The next questions are whether this supervised approach works in routine care, how results vary in other populations, and whether strength gains last. The authors identify practical delivery and long-term outcomes as gaps. Forty weeks cannot answer what happens years later.
T-REx also did not test a compounded preparation. Tirzepatide or semaglutide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The FDA's compounding explanation, current as of September 16, 2025, says it does not verify these preparations' safety, effectiveness or quality before marketing.
A licensed provider may still prescribe — that decision is between you and your doctor.
At Promise, a licensed provider reviews every request, and not everyone qualifies. The useful visit brings together current strength, symptoms, other medicines and what activity is realistic. The prescriber sets the medication dose; a trial average cannot set an individual's plan.





